Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC — Stella

Recruiting

Back to Small Cell Lung Cancer Recurrent trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Cancer hospital Fudan University, Shanghai, Shanghai Municipality

Key details

Sponsor

Fudan University

Enrollment target

~39 participants

Started

April 2024

Primary completion

April 2026

Age range

18 Years – 75 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov